Warrant [Member]
Class of Warrant or Right [Axis]
Restricted Stock Units (RSUs) [Member]
Award Type [Axis]
Equity Components [Axis]
Stock Option Plan [Member]
Options Granted To Consultants [Member]
2007 Incentive Stock And Awards Plan [Member]
Range One [Member]
Exercise Price Range [Axis]
Options Granted To Employees [Member]
Tranche Four [Member]
Vesting [Axis]
Mr. Mark Baum [Member]
Title of Individual [Axis]
Tranche Five [Member]
Lender Warrants [Member]
Related Party [Axis]
Warrants Issued In April 2012 Private Placement [Member]
Underwriter Warrants [Member]
Minimum [Member]
Range [Axis]
Maximum [Member]
Mark Baum [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Tranche One [Member]
Tranche Two [Member]
Tranche Three [Member]
Consultant Tranche 1 [Member]
Consultant Tranche 2 [Member]
Consultant Tranche 3 [Member]
Consultant Tranche 4 [Member]
Consultant Tranche 5 [Member]
Warrants Issued To Investor Relations Consultant [Member]
Warrants Issued To Investor Relations Consultant [Member]
PCCA License Agreement [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
PCCA Strategic Alliance Agreement [Member]
Restricted Stock Units One [Member]
Warrant [Member]
Customer Relationships [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Trade Name [Member]
Non-Competition Clause [Member]
State Pharmacy Licenses [Member]
Restricted Stock [Member]
Class of Stock [Axis]
Pharmacy Creations, LLC [Member]
Park [Member]
Business Acquisition [Axis]
Period Ending March 31, 2016 [Member]
Report Date [Axis]
Employees And Directors [Member]
Employees [Member]
Selling And Marketing [Member]
Income Statement Location [Axis]
General And Administrative [Member]
Research And Development [Member]
Directors [Member]
Consultants [Member]
Urigen Pharmaceuticals, Inc [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Dr. Robert Kammer [Member]
Baum Performance Equity Award [Member]
Monte Carlo Simulation [Member]
Plan Name [Axis]
Monte Carlo Simulation One [Member]
Non-Employee Directors [Member]
Andrew R. Boll [Member]
Former Directors [Member]
Non-Competition Clause [Member]
Stock Options [Member]
Option Indexed to Issuer's Equity, Type [Axis]
Lease Agreement [Member]
Lease Arrangement, Type [Axis]
April 1, 2015 [Member]
Life Sciences Alternative Funding LLC [Member]
Loan Agreement [Member]
May 11, 2015 [Member]
Billing And Collection Agreement [Member]
Third Party [Member]
Sellers [Member]
Park Compounding [Member]
Non-Employee Director [Member]
John P. Saharek [Member]
Boll Performance Equity Award [Member]
Sublease Agreement [Member]
Financial Instrument [Axis]
May 11, 2016 [Member]
Minimum Revenue or Cash Balance [Member]
Concentration Risk Benchmark [Axis]
12.5 Note Payable [Member]
Debt Instrument [Axis]
Transition Period [Member]
FDA [Member]
Loans Insured or Guaranteed by Government Authorities [Axis]
Asset Purchase Agreements [Member]
Other 2015 Acquisitions [Member]
Patents [Member]
Trademarks [Member]
Greater Than $9.00 (the "First Price Condition) [Member]
Greater Than $10.00 (the "Second Price Condition) [Member]
Greater Than $12.00 (the "Third Price Condition) [Member]
Greater Than $14.00 (the "Fourth Price Condition) [Member]
Greater Than $15.00 (the "Fifth Price Condition) [Member]
2007 Incentive Stock and Awards Plan [Member]
Accumulated Deficit [Member]
Acquisition of Pharmacy Creations [Member]
Acquisition of Park [Member]
Mr. Boll [Member]
Sales Agreement [Member]
Agreement [Axis]
Federal [Member]
Income Tax Authority [Axis]
Research And Development Tax Credit Carryforward [Member]
Income Tax Authority, Name [Axis]
State Income Tax [Member]
Commercial Lease Agreement [Member]
Subsequent Event [Member]
Subsequent Event Type [Axis]
LSAF Note [Member]
Underwriting Agreement [Member]
Underwriters [Member]
Offering Of Common Stock [Member]
Cantor Fitzgerald [Member]
Deferred Acquisition Obligations, Stock Options, Unvested RSUs and Warrants [Member]
Antidilutive Securities [Axis]
Note Purchase Agreement [Member]
8.00% Convertible Senior Secured Note [Member]
Lender [Member]
Senior Note - 2015 [Member]
Convertible Senior Note - 2016 [Member]
Warrant Derivative Liability [Member]
Liability Class [Axis]
Embedded Conversion Feature Derivative Liability [Member]
Mark L. Baum [Member]
April 2016 [Member]
License Agreement [Member]
Urigen Pharmaceuticals, Inc. [Member]
Notes Payable [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Filer Category
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets
Cash and cash equivalents
Restricted short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Intangible assets, net
Goodwill
Furniture and equipment, net
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of deferred acquisition obligation and accrued interest
Current portion of contingent acquisition obligation
Current portion of capital lease obligations
Total current liabilities
Capital lease obligations, net of current portion
Deferred acquisition obligation, net of current portion
Accrued expenses, net of current portion
Deferred tax liability
Notes payable and paid-in-kind interest, net of unamoritzed debt discount
Note payable and paid-in-kind interest, net of unamortized debt discount
Convertible note payable, net of unamortized debt discount
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $0.001 par value, 90,000,000 shares authorized, 13,105,678 and 9,755,678 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively
Additional paid-in capital
Accumulated deficit
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues:
Sales, net
License revenues
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling and marketing
General and administrative
Research and development
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Change in fair value of derivative liabilities
Other income
Total other income (expense), net
Net loss
Basic and diluted net loss per share of common stock
Weighted average number of shares of common stock outstanding, basic and diluted
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of furniture and equipment
Amortization of intangible assets
Amortization of debt discount
Paid-in-kind added to principal of note payable
Non-cash gain on contingent acquisition obligations
Change in fair value of derivative liabilities
Stock-based compensation
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH USED IN OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Park Compounding, net of cash
Investment in patent and trademark assets
Purchases of furniture and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations
Net proceeds from public equity offering
Payments on Park deferred acquisition obligation
Proceeds from convertible note payable, net of issuance costs and fees
Net proceeds from exercise of warrants and stock options
Payments for deferred offering costs
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
NET CHANGE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of period
CASH AND CASH EQUIVALENTS, end of period
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of embedded conversion feature recorded as debt discount and derivative liability
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering
Reclassification of the fair value of the LSAF additional paid-in capital to derivative liability
Reclassification of the fair value of the LSAF derivative liability to additional paid-in capital upon closing of the public equity financing
Issuance of common stock and fair value of deferred acquisition obligations related to the purchase of Park Compounding
Issuance of stock options for consulting services included in accounts payable and accrued expenses
Purchase of furniture and equipment included in accounts payable and accrued expenses
Accounting Policies [Abstract]
Description of Business and Basis of Presentation
Summary of Significant Accounting Policies
Restricted Short-term Investments
Restricted Short-Term Investments
Inventory Disclosure [Abstract]
Inventories
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses
Debt Disclosure [Abstract]
Debt
Equity [Abstract]
Stockholders' Equity (Deficit) and Stock-Based Compensation
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information and Concentrations
Subsequent Events [Abstract]
Subsequent Events
Use of Estimates
Liquidity
Concentrations of Credit Risk
Accounts Receivable
Revenue Recognition and Deferred Revenue
Debt Issuance Costs and Debt Discount
Fair Value Measurements
Derivative Instruments
Third Party Billing and Collection Agreements
Stock-Based Compensation
Income Taxes
Basic and Diluted Net Loss per Common Share
Recently Issued Accounting Pronouncements
Schedule of Basic and Diluted Earnings Per Common Share
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Intangible Assets
Schedule of Amortization Expenses for Intangible Assets
Schedule of Estimated Future Amortization Expense
Schedule of Accounts Payable and Accrued Expenses
Summary of Notes Payable
Summary of Future Minimum Payments
Schedule of Stock Option Plan Activity
Schedule of Fair Value Assumption
Schedule of Shares Outstanding and Exercisable
Schedule of Restricted Stock Units Activity
Schedule of Warrants Activity
Schedule of Warrants Outstanding and Warrants Exercisable
Schedule of Stock Based Compensation Granted to Employees Directors Consultants
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Derivative Liabilities at Fair Value
Fair Value at Reconciliation of Measured Liabilities
Statement [Table]
Statement [Line Items]
Net loss
Net cash used in operating activity
Cash resources and restricted investments
Deposit coverage limits by FDIC, per owner
Cash deposits in excess of FDIC limits
Accounts receivable, net of allowance for doubtful accounts
Percentage of billing and collection amount
Billing and collection management expense
Due to related party
Anti dulitive securities
Number of shares vested during the period
Numerator - net loss
Denominator - weighted average number of shares outstanding, basic and diluted
Net loss per share, basic and diluted
Restricted Short-term Investments Details Narrative
Certificate of deposit
Raw materials
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Deposits and other current assets
Total prepaid expenses and other current assets
Amortization periods (in years)
Amortization periods description
Cost
Accumulated amortization
Net Carrying value
2016
2017
2018
2019
2020
Thereafter
Intangible assets
Accounts payable
Deferred rent
Accrued interest (see Note 8)
Accrued exit fee for note payable (see Note 8)
Building lease liability (1)
Other accrued expenses (2)
Total accounts payable and accrued expenses
Less: Current portion
Non-current total accrued expenses
Area of office space
Area of previous office space
Monthly rent amount
Recognized lease losses related to estimated remaining lease liability
Stock based compensation accrual
Additional paid-in-capital
Principal amount of loan
Loans bear interest
loans bear interest rate description
Loan installments
Percentage of loan agreement final fee
Loan due date
Incurred expense debt
Liability of final fee included in accrued expenses
Issuance of warrants to purchase maximum number of shares
Common stock exercise price per share
Issuance of warrants to purchase of common stock expiration year
Fair value of warrants
Fair value of common stock
Fair value of contractual term
Common stock volatility rate
Fair value of dividend rate
Fair value of risk-free interest rate
Debt discount
Convertible note principal amount
Convertible note fixed per annum rate
Convertible note description
Debt conversion price per share
Proceeeds from convertible note
Percentage of repurchase convertible note in cash is greater than outstanding principal amount
Fair value of embedded conversion feature
Warrants exercise price per share
Notes payable
Add: Interest paid-in-kind
Less: Discounts on notes
Less: Current portion
Long-term portion
Remainder of 2016
2017
2018
2019
2020
Thereafter
Total minimum payments
Less: amount representing interest and interest paid-in-kind
Notes payable, gross
Add: interest paid-in-kind
Less: unamortized discount
Notes payable and interest paid-in-kind, net of unamortized debt discount
Consultant Tranche 1 [Axis]
Number of common stock shares issued for offering
Additional common stock shares issued during the period
Sale of stock price per share
Number of shares sold under the agreement
proceeds from sale of common stock approximately
Percentage of cash commission
Proceeds from offering price
Available for future sales of shares
Shares issued upon exercise of stock options, shares
Shares issued upon exercise of stock options
Stock options to purchase shares of common stock
Stock option purchase of exercise price
Preferred stock, shares authorized
Preferred stock, par value
Preferred stock, shares issued
Preferred stock, shares outstanding
Maximum number of common stock issuance under the plan
Intrinsic value of stock option exercised
Stock options granted with exercise price contractual terms
Stock options granted vesting terms
Percentage of forfeiture factor
Unrecognized compensation expense related to unvested stock options granted under the Plan
Expense expected to recognize over the weighted-average remaining vesting period
Number of shares, Outstanding, Beginning balance
Number of shares, Options granted
Number of shares, Options exercised
Number of shares, Options cancelled/forfeit
Number of shares, Outstanding, Ending balance
Number of shares, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Options granted
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeit
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Exercise Price, Vested and expected to vest - end of period
Weighted Avg. Remaining Contractual Life, Options outstanding
Weighted Avg. Remaining Contractual Life, Options exercisable
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options outstanding
Aggregate Intrinsic Value, Options exercisable
Aggregate Intrinsic Value, Options vested and expected to vest
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility
Expected volatility, minimum
Expected volatility, maximum
Risk-free interest rate
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Number of RSUs unvested, Outstanding, Beginning balance
Number of RSUs vested
Number of RSUs unvested, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Beginning balance
Weighted Average Grant Date Fair Value, RSUs vested
Weighted Average Grant Date Fair Value, Ending balance
Number of shares, Outstanding, Beginning balance
Number of Shares Subject to Warrants Outstanding, Granted
Number of Shares Subject to Warrants Outstanding, Exercised
Number of Shares Subject to Warrants Outstanding, Expired/forfeited
Number of shares, Outstanding, Ending balance
Weighted average remaining contractual life of the outstanding warrants in years
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Granted
Weighted Avg. Exercise Price, Exercised
Weighted Avg. Exercise Price, Expired/forfeited
Weighted Avg. Exercise Price, Outstanding, Ending balance
Issue Date
Warrants Outstanding
Exercise Price
Warrants Exercisable
Expiration Date
Stock based compensation related to equity instruments granted to related parties
Warrants expiration date
Convertible note matures date
Expected volatility
Risk-free interest rate
Dividend yield
Balance Beginning
Embedded conversion feature in Convertible Note issued
Modification of warrant and reclassification from equity to liabilities
Change in fair value
Reclassification from liabilities to equity upon closing of public equity offering
Balance Ending
Revenue
Number of common stock shares issued for exceeds revenue value
Fair value of divided ratio
Number of common stock shares issued for maximum exceeds from revenue
Fair value of contingent acquisition obligation
Unpaid royalties
Asset purchase, license and commission expense
Maximum percentage of sales derived from single customer
Percentage of drug and chemical purchases from three main suppliers
Number of common stock shares issued for services
Acquisition of Park [Member]
Acquisition of Pharmacy Creations [Member]
Agreement [Axis]
Andrew R Boll [Member]
April One Two Thousand Fifteen [Member]
Asset Purchase Agreements [Member]
Baum Performance Equity Award [Member]
Billing And Collection Agreement [Member]
Billing And Collection Management Expense.
Boll Performance Equity Award [Member]
Building Lease Liability.
Cantor Fitzgerald [Member]
Commercial Lease Agreement [Member]
Consultant
Consultant Tranche Five [Member]
Consultant Tranche Four [Member]
Consultant Tranche One [Member]
Consultant Tranche Three [Member]
Consultant Tranche Two [Member]
Debt Interest And Interest Paid in kind.
Deferred Acquisition Obligation And Accrued Interest Current.
Deferred Acquisition Obligation Noncurrent.
Payments for deferred offering costs.
Dr Robert Kammer [Member]
Employees And Directors [Member]
Employees [Member]
Fifth Price Condition [Member]
First Price Condition [Member]
Former Directors [Member]
Fourth Price Condition [Member]
Gain On Contingent Acquisition Obligations.
General And Administrative [Member]
Interest paid-in-kind.
Issuance Of Common Stock And Fair Value Of Deferred Acquisition Obligations Related To Purchase Of Business.
Issuance of warrants to purchase of common stock expiration year.
John .P Saharek [Member]
LSAF Note [Member]
Lease Agreement [Member]
Lender Warrants [Member]
Life Sciences Alternative Funding LLC [Member]
Liquidity Disclosure [Policy Text Block]
Loan Agreement [Member]
Mark Baum [Member]
Maximum deposit coverage limits.
May Eleven Two Thousand Fifteen [Member]
May Eleven Two Thousand Sixteen [Member]
Minimum Revenue Or Cash Balance [Member]
Monte Carlo Simulation [Member]
Monte Carlo Simulation One [Member]
Mr. Boll [Member]
Mr Mark Baum [Member].
Non Competition Clause [Member]
Non Employee Director [Member]
Non Employee Directors [Member]
Offering Of Common Stock [Member]
Options granted to employees
Options granted to consultants
Other Two Thousand FiFteen Acquisitions [Member].
PCCA License Agreement [Member]
PCCA Strategic Alliance Agreement [Member]
Park Compounding [Member]
Park [Member]
Percentage of billing and collection amount.
Percentage of cash commission.
Percentage of drug and chemical purchases from three main suppliers.
Percentage of forfeiture factor.
Percentage of loan agreement final fee.
Period Ending March 31, 2016 [Member]
Pharmacy Creations Llc [Member].
Previous Office Space Area.
Purchase of furniture and equipment included in accounts payable and accrued expenses.
Range five [member]
Range four [member].
Range one [member].
Range three [member].
Range two [member].
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering.
Recognized lease losses related to estimated remaining lease liability.
Research And Development [Member]
Restricted Stock Units RSU One [Member].
Accumulated Deficit [Member]
Sales Agreement [Member]
Schedule Of Prepaid Expenses And Other Current Assets [TableTextBlock].
Schedule of warrants outstanding and exercisable [Table Text Block]
Second Price Condition [Member]
Sellers [Member]
Selling And Marketing [Member]
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
Share Based Compensation Award Tranche Five [Member]
Share Based Compensation Award Tranche Four [Member]
Warrants Exercisable
Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term
StockOptionPlanMember
Sublease Agreement [Member]
Summary of Future Minimum Payments [Table Text Block].
Third Party Billing And Collection Agreements [Policy Text Block]
Third Party [Member]
Third Price Condition [Member]
Transition Period [Member]
12.5 Note Payable [Member]
2007 Incentive Stock and Awards Plan [Member]
2007 Incentive Stock And Awards Plan [Member]
U.S. Food And Drug Administration [Member]
Underwriter Warrants [Member].
Underwriters [Member]
Underwriting Agreement [Member]
Urigen Pharmaceuticals Inc [Member]
Warrant
Warrants Expiration Date.
Warrants Issuance Date.
Warrants Issued In April Two Thousand Twelve Private Placement [Member]
Warrants Issued To Investor Relations Consultant One [Member]
Warrants Issued To Investor Relations Consultant Two [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Reclassification From Liabilities To Equity Upon Closing Of Public Equity Offering.
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Modification Of Warrant And Reclassification From Equity To Liabilities.
Fair Value Liabilities Measured On Recurring Basis Unobservable Inputeconciliation Embedded Conversion Feature In Convertible Note Issued.
Number of common stock shares issued for exceeds revenue value.
Number of common stock shares issued for maximum exceeds from revenue.
Additional common stock shares issued during the period.
WarrantsIssuedToInvestorRelationsConsultantTwoMember
WarrantActivityMember
NonCompetitionClauseMember
Assets, Current
Assets
Liabilities, Current
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Revenue, Net
Health Care Organization, Medical Supplies and Drugs Expense
Gross Profit
Operating Costs and Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
GainOnContingentAcquisitionObligations
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Customer Deposits
Payments to Acquire Businesses, Net of Cash Acquired
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Repayments of Debt and Capital Lease Obligations
Payments of Financing Costs
Net Cash Provided by (Used in) Financing Activities
Cash and Cash Equivalents, Period Increase (Decrease)
Inventory Disclosure [Text Block]
Derivatives, Policy [Policy Text Block]
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Accounts Payable and Accrued Liabilities
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
Long-term Debt, Maturities, Repayments of Principal in Year Two
Long-term Debt, Maturities, Repayments of Principal in Year Three
Long-term Debt, Maturities, Repayments of Principal in Year Four
Long-term Debt, Maturities, Repayments of Principal after Year Five
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs